Dopamine and serotonin receptors: Amino acid sequences, and clinical role in neuroleptic parkinsonism

Japanese Journal of Pharmacology

Volumn 71, Issue 3, 1996, Pages 187-204

  Seeman, Philip ^a   Corbett, Roy ^b   Nam, Diane ^a   Van Tol, Hubert H M ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SANOFI   (France)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotic drug; Catalepsy; Clozapine; Dopamine D4 receptor; Parkinsonism; Serotonin 2 receptor

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; LOXAPINE; MELPERONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERLAPINE; QUETIAPINE; RACLOPRIDE; RADIOLIGAND; REMOXIPRIDE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; SERTINDOLE; THIORIDAZINE; TRIFLUOPERAZINE;

AMINO ACID SEQUENCE; CATALEPSY; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; MEMBRANE; NONHUMAN; PARKINSONISM; PARTITION COEFFICIENT; PROTEIN VARIANT; PSYCHOSIS; RAT; REVIEW; SOLUBILITY;

EID: 0029841131     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.71.187     Document Type: Review

References (140)

1. 2 receptor. Eur J Pharmacol (Mol Pharmacol Sect) 227, 205-214 (1992)
2. 2 receptors. J Neurochem 59, 627-635 (1992)
3. GLYCINE194, in Africans, but not in Caucasians. No association with schizophrenia. Am J Med Gen (Neuropsychiatric Genet) 54, 384-390 (1994)
4. Hibert MF, Trumpp-Kallmeyer S, Bruinvels A and Hoflack J: Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol Pharmacol 40, 8-15 (1991)
5. Neve KA, Cox BA, Henningsen RA, Spanoyannis A and Neve RL: Pivotal role for aspartate-80 in the regulation of dopa- mine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol Pharmacol 39, 733-739 (1991)
6. 2-adrenergic receptor-G-protein interactions. J Biol Chem 269, 29557-29564 (1994)
7. 355Asn site directed mutagenesis. Biochem Pharmacol 44, 1917-1920 (1992)
8. 1B receptors. Nature 360, 161-163 (1992)
9. 1B receptors. J Neurochem 60, 380-383 (1993)
10. 1F receptors for beta-adrenergic antagonists. Neuropharmacology 33, 387-391 (1994)
11. Civelli O, Bunzow JR, Grandy DK, Zhou Q-Y and Van Tol HHM: Molecular biology of the dopamine receptors. Eur J Pharmacol (Mol Pharmacol Sect) 207, 277-286 (1991)
12. Peroutka SJ: Molecular biology of serotonin (5-HT) receptors. Synapse 18, 241-260 (1994)
13. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR and Humphrey PPA: VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46, 157-203 (1994)
14. Lucas JJ and Hen R: New players in the 5-HT receptor field: genes and knockouts. Trends Pharmacol Sci 16, 246-252 (1995)
15. Valine194Glycine, is insensitive to dopamine and clozapine. Report of a homozygous individual. Am J Med Gen 61, 277-282 (1996)
16. Seeman P, Wong M and Lee T: Dopamine receptor-block and nigral fiber-impulse blockade by major tranquilizers. Fed Proc 33, 246 (1974)
17. Seeman P, Chau-Wong M, Tedesco J and Wong K: Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci USA 72, 4376-4380 (1975)
18. Creese I, Burt DR and Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs. Science 192, 481-483 (1976)
19. Seeman P: Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2, clozapine occupies D4. Neuropsychopharmacology 7, 261-284 (1992)
20. Seeman P: Dopamine receptors and psychosis. [Scientific American] Science and Medicine 2, 28-37 (1995)
21. Meltzer HY and Nash JF: Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43, 587-604 (1991)
22. Meltzer HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berlin) 99, S18-S27 (1989)
23. Meltzer HY: The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 15, Supp 1, 2S-3S (1995)
24. Leysen JE, Megens AAHH, Janssen PMF and Schotte A: Finely balanced 5HT2/D2-antagonism: A crucial factor for the treatment of schizophrenia. Neuropsychopharmacology 10, Supp 3, 467S (1994)
25. Huttunen M: The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 15, Supp 1, 4S-10S (1995)
26. 3 receptors. Mol Pharmacol 43, 749-754 (1993)
27. 4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol (Mol Pharmacol Section) 291, 59-66 (1995)
28. Seeman P: Therapeutic receptor-blocking concentrations of neuroleptics. Int Clin Psychopharmacol 10, Supp 3, 5-13 (1995)
29. 4 receptor clones depends on the radioligand used. Soc Neurosci Abstr 21, 252.1 (1995)
30. 3H]clozapine binding sites in rat brain. J Neural Transm 101, 51-64 (1995)
31. 4 receptors in rat frontal cortex. J Neural Transm 101, 231-235 (1995)
32. 6 serotonin receptors may reflect psychoactive profile. Mol Med 1, 398-406 (1995)
33. Kawagoe KT, Garris PA, Wiedemann DJ and Wightman RM: Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 51, 55-64 (1992)
34. Asghari V, Schoots O, Van Kats S, Ohara K, Jovanovic V, Guan H-C, Bunzow JR, Petronis A and Van Tol HHM: Dopamine D4 receptor repeat: Analysis of different native and mutant forms of the human rat genes. Mol Pharmacol 46, 364-373 (1994)
35. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49, 538-544 (1992)
36. Olesen OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen N-A, Refshammer C, Sorensen J, Bysted M, Christensen J and Rosenberg R: Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology (Berlin) 117, 371-378 (1995)
37. Meltzer HY, Kennedy J, Dai J, Parsa M and Riley D: Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. Neuropsychopharmacology 12, 39-45 (1995)
38. 2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55, 1-3 (1994)
39. Nordström A-L: The mechanism of antipsychotic drug action examined by PET in schizophrenic patients. Neuropsychopharmacology 10, Supp 3, Part 1, 695S (1994)
40. 2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm 86, 163-173 (1991)
41. 18FESP. In New Generation of Antipsychotic Drugs: Novel Mechanisms of Action, Vol. 4, Edited by Brunello N, Mendlewicz J and Racagni G, pp 130-135, International Academy for Biomedical Drug Research, Karger, Basel (1993)
42. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY and Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268, 1403-1410 (1994)
43. Seeman P: Dopamine receptors. Clinical correlates. In Psychopharmacology: The Fourth Generation of Progress, Edited by Bloom FE and Kupfer DJ, pp 295-302, Raven Press, New York (1995)
44. 3H]-raclopride: implications for positron emission tomography of the human brain. Synapse 3, 96-97 (1989)
45. 3H]raclopride binding in the rat brain. Synapse 9, 188-194 (1991)
46. 11C-raclopride and positron emission tomography. J Neurosci 12, 3773-3780 (1992)
47. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13, 350-356 (1993)
48. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, Fowler JS, Volkow ND and Wolf AP: Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 90, 11816-11820 (1993)
49. 123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 10, 177-184 (1992)
50. Wong DF, Hong C, Yokoi F, Grunder G, Schlaepfer T, Szymanski S, Imperial A, Pearlson G, Nestadt G, Ravert H, Dannais R, Angrist B and Gjedde A: Quantification of human intrasynaptic dopamine release by iv cocaine and amphetamine. Am Coll Neuropsychopharmacol 34, 227 (1995)
51. De Jesus OT, Van Moffaert GJC, Dinerstein RJ and Friedman AM: Exogenous I-DOPA alters spiroperidol binding, in vivo, in the mouse striatum. Life Sci 39, 341-349 (1986)
52. 18F]N-methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons. Synapse 9, 195-207 (1991)
53. 18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography. Synapse 7, 324-327 (1991)
54. Laruelle M, Abi-Dargham A, Van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF and Innis RB: SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36, 1182-1190 (1995)
55. Laruelle M, Abi-Dargham A, Gil R, Van Dyck CH, Erdos J, D'Souza D, Rosenblatt W, McChance-Katz E, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Hoffer PB, Krystal J, Charney DS and Innis RB: SPECT imaging of synaptic dopamine release in drug-free schizophrenic patients. Am Coll Neuropsychopharmacol (Abstr) 34, 159 (1995)
56. Andén N-E and Stock G: Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25, 346-348 (1973)
57. Bowers MB Jr: Homovanillic acid in caudate and pre-frontal cortex following neuroleptics. Eur J Pharmacol 99, 103-105 (1984)
58. Gefvert O, Lindstrom LH, Langstrom B, Bergstrom M, Lundberg T, Yates RA, Larsson SD and Tuersley MD: Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg Seroquel™ (ICI 204,636) TID. Am Coll Neuropsychopharmacol 34, 276 (1995)
59. Laruelle M, Abi-Dargham A, Gil R, Van Dyck CH, Erdos J, D'Souza D, Rosenblatt W, McChance-Katz E, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Hoffer PB, Krystal J, Charney DS and Innis RB: SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia. Schizophrenia Res 18, 198-199 (1996)
60. Seeman P: Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatry Scand 82, Supp 358, 14-20 (1990)
61. Rupard JH, de Paulis T, Janowsky A and Smith HE: Sterically hindered 5,1-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem 32, 2261-2268 (1989)
62. Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45, 789-796 (1988)
63. Smith GS, Dewey SL, Logan J, Brodie JD, Vitkun S, Simkowitz P, Alexoff D, Fowler JS, Volkow ND and Wolf AP: The serotonin-dopamine interaction measured with positron emission tomography (PET) and C-11 raclopride in normal human subjects. J Nucl Med 35, 85P (1994)
64. Dewey SL, Smith GS, Logan J, Alexoff D, Ding Y-S, King P, Pappas N, Brodie JD and Ashby CR Jr: Serotonergic modulation of striatal dopamine measured with positron emission tomograpghy (PET) and in vivo microdialysis. J Neurosci 15, 821-829 (1995)
65. Pehek EA: Systemic and intracortical administration of ritanserin increases in vivo dopamine release in rat prefrontal cortex. Schizophrenia Res 15, 161 (1995)
66. Bligh-Glover W, Jaskiw GE, Vrtunski B, Ubogy D and Meltzer HY: 5HT2-Receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophrenia Res 15, 153-154 (1995)
67. Wadenberg M-L: Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Transm 89, 49-59 (1992)
68. Jaskiw GE, Ubogy D and Meltzer HY: Clozapine's inability to induce experimental catalepsy is not altered by changes in serotonergic transmission. Soc Neurosci Abstr 20, 225 (1994)
69. 2 antagonist ritanserin in neuroleptic-induced ParkinsonismA double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13, 500-506 (1990)
70. Miller CH, Hummer M, Pycha R and Fleischhacker WW: The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: Case reports. Prog Neuropsychopharmacol Biol Psychiatry 16, 247-251 (1992)
71. Casey DE: The effect of a serotonin S2 antagonist, ritanserine, and an anticholinergic benztropine on haloperidol-induced dystonia in nonhuman primates. Am Coll Neuropsychopharmacol (Abstr) 30, 127 (1991)
72. Casey DE: Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology (Berlin) 112, S55-S59 (1993)
73. Casey DE: Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 10, Supp 3, 105-114 (1995)
74. Casey DE: The nonhuman primate model: Focus on dopamine D2 and sertonin mechanisms. In Schizophrenia, Alfred Benzon Symposium 38, Edited by Fog R, Gerlach J and Hemmingsen R, pp 287-297, Munksgaard, Copenhagen (1995)
75. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27, 515-518 (1988)
76. Broekkamp CLE, Oosterloo SK, Berendsen HHG and van Delft AML: Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch Pharmacol 338, 191-195 (1988)
77. Hicks PB: The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47, 1609-1615 (1990)
78. Wadenberg ML and Ahlenius S: Antipsychotic-like profile of combined treatment with raclopride and 8-OHDPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 83, 43-53 (1991)
79. Casey DE: The effect of 8-OH-DPAT on haloperidol-induced dystonia in nonhuman primates. Am Coll Neuropsychopharmacol (Abstr) 32, 109 (1992)
80. Neal-Beliveau BS, Joyce JN and Lucki I: Serotonergic involve- ment in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265, 207-217 (1993)
81. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21, 301-314 (1982)
82. 2 receptors of normal human brain in vitro. Eur J Pharmacol 143, 279-282 (1987)
83. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K and Dunn RW: Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berlin) 120, 67-74 (1995)
84. i values. J Pharmacol Exp Ther 251, 238-246 (1989)
85. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25, 390-392 (1989)
86. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265, 498-508 (1993)
87. 2 receptors. J Pharmacol Exp Ther 266, 1374-1384 (1993)
88. 2 receptor studies. Neuropsychopharmacology 3, 361-369 (1990)
89. 1C receptor antagonists. Eur J Pharmacol 245, 179-182 (1993)
90. 6 serotonin receptor. J Neurochem 66, 47-56 (1996)
91. 1A receptors. Eur J Pharmacol 260, 79-83 (1994)
92. 3 recognition sites: fact or artifact? Eur J Pharmacol 171, 137-139 (1989)
93. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berlin) 120, 365-368 (1995)
94. Daniel D, Targum S, Zimbroff D, Mack R, Zborowski J, Morris D, Sebree T and Wallin B: Efficacy, safety, and dose response of three doses of sertindole and three doses of Haldol in schizophrenic patients. Am Coll Neuropsychopharmacol (Abstr) 34, 278 (1995)
95. Sunahara RK, Niznik HB, Weiner DM, Stormann TM, Brann MR, Kennedy JL, Gelernter JE, Rozmahel R, Yang Y, Israel Y, Seeman P and O'Dowd BF: Human dopamine D, receptor encoded by an intronless gene on chromosome 5. Nature 347, 80-83 (1990)
96. 2 dopamine receptor. Proc Natl Acad Sci USA 86, 9762-9766 (1989)
97. 3 humain et identification de son chromosome. Comptes Rendu Acad Sci Paris 311, 501-508 (1990) (in French)
98. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610-614 (1991)
99. Van Tol HHM, Wu CM, Guan H-C, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB and Jovanovic V: Multiple dopamine D4 receptor variants in the human population. Nature 358, 149-152 (1992)
100. 1. Nature 350, 614-619 (1991)
101. 1A receptor is intact in mood disorders. Neuropsychopharmacology 12, 263-268 (1995)
102. 1A serotonin receptor. Mol Pharmacol 43, 516-520 (1993)
103. 1D-type serotonin receptor. Mol Pharmacol 40, 143-148 (1991)
104. 1D subtype. J Biol Chem 267, 7553 -7562 (1992)
105. Demchyshyn L, Sunahara RK, Miller K, Teitler M, Huffman BJ, Kennedy JL, Seeman P, Van Tol HHM and Niznik HB: A human serotonin ID receptor variant (5HT1Dβ) encoded by an intronless gene on chromosome 6. Proc Natl Acad Sci USA 89, 5522-5526 (1992)
106. 1B receptor. J Biol Chem 267, 5735-5738 (1992)
107. 1D beta. Proc Natl Acad Sci USA 89, 3630-3634 (1992)
108. Levy FO, Gudermann T, Birnbaumer M, Kaumann AJ and Birnbaumer L: Molecular cloning of a human gene (S31) encoding a novel serotonin receptor mediating inhibition of adenylyl cyclcase. FEBS Lett 296, 201-206 (1992)
109. 1E receptor. Mol Pharmacol 42, 180-185 (1992)
110. McAllister G, Charlesworth A, Snodin C, Beer MS, Noble AJ, Middlemiss DN, Iversen LL and Whiting P: Molecular cloning of a serotonin receptor from human brain (5HT1E): A fifth 5HT1-like subtype. Proc Natl Acad Sci USA 89, 5517-5521 (1992)
111. 2 receptor is encoded by a multiple intron-exon gene. Mol Br Res 14, 20-26 (1992)
112. 2B receptor. Mol Pharmacol 46, 227-234 (1994)
113. Saltzmann AG, Morse B, Whitman MM, Ivanshchenko Y, Jaye M and Felder S: Cloning of the human serotonin 5-HT1C receptor subtypes. Biochem Biophys Res Commun 181, 1469-1478 (1991)
114. 4 receptor: molecular cloning and pharmacological characterization of two splice variants. EMBO J 14, 2806-2815 (1995)
115. 4L receptor. Soc Neurosci Abstr 20, 1266 (1994)
116. 5A serotonin receptor. FEBS Lett 355, 242-246
117. 7) positively linked to adenylate cyclase. J Biol Chem 268, 23422-23426 (1993)
118. 2 dopamine receptor cDNA. Nature 336, 783-787 (1988)
119. 50) of an enzymatic reaction. Biochem Pharmacol 22, 3099-3108 (1973)
120. Owolabi J, Martin A, Rampersad V, Hoo K and Kamboj RK: Construction and characterization of stable mammalian cell lines expressing human D4 dopamine receptors. Can J Physiol Pharmacol 72, Supp 1, 383 (1994)
121. O'Dowd BF, Nguyen T, Tirpak A, Jarvie KR, Israel Y, Seeman P and Niznik HB: Cloning of two additional catecholamine receptors from rat brain. FEBS Lett 262, 8-12 (1990)
122. 2 receptors. J Neural Transm (1995) (in press)
123. Stille G, Lauener H, Eichenberger E, Hunziker F and Schmutz J: Über eine neue chemische Gruppe stark wirksamer Neuroleptica. 5. Mittelung über siebengliederige Heterocylclen. Arzneimittelforschung 15, 841-843 (1965) (in German)
124. Schmutz J: Absicht und Zufall in der Arznmittelforschung, dargelegt am beispiel der trizyklischen Psychopharmaka. Pharmaceut Acta Helv 48, 117-132 (1973) (in German)
125. Schmutz J and Eichenberger E: Clozapine. In Chronicles of Drug Discovery, Edited by Bindra JS and Lednicer D, Vol 1, pp 39-59, John Wiley, New York (1992)
126. Nguyen T, Jin H, Taruscio D, Ward D, Kennedy JL, Seeman P and O'Dowd BF: Human dopamine D5 receptor human pseudogenes. Gene 109, 211-218 (1991)
127. 2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. J Am Med Assoc 271, 204-208 (1994)
128. Itokawa M, Arinami T, Futamura N, Hamaguchi H and Toru M: A structural polymorphism of human dopamine D2 receptor. Biochem Biophys Res Commun 196, 1369-1375 (1993)
129. 3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatric Gen 2, 249-256 (1992)
130. 3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci USA 90, 8942-8946 (1993)
131. Nagai Y, Ueno S, Saeki Y, Soga F and Yanagihara T: Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem Biophys Res Commun 194, 368-374 (1993)
132. Snyder LA, Roberts JL and Sealfon SC: Alternative transcripts of the rat and human dopamine D3 receptor. Biochem Biophys Res Commun 180, 1031-1035 (1991)
133. 4 (DRD4) gene. Hum Mol Gen 2, 767-773 (1993)
134. 4 receptor gene in psychotic patients. Biol Psychiatry 34, 459-464 (1993)
135. 1A gene. Am J Med Gen (Neuropsychiatry Gen) 60, 393-399 (1995)
136. Lam S, Shen Y, Nguyen T, Messier TL, Bran M, Comings D, George SR and O'Dowd BF: A serotonin receptor gene (5HT1A) variant found in a Tourette's syndrome patient. Biochem Biophys Res Commun 219, 853-858 (1996)
137. Nöthen MM, Erdmann J, Shimron-Abarbanell D and Propping P: Identification of genetic variation in the human serotonin 1Dbeta receptor gene. Biochem Biophys Res Commun 205, 1194-1200(1994)
138. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 90, 408-412 (1993)
139. 2C receptor gene (HTR2C). Genomics 27, 274-279 (1995)
140. 5B receptors: define a new family of serotonin receptors: Cloning, functional expression, and chromosomal localization. Mol Pharmacol 43, 313-319 (1993)